Literature DB >> 16152604

Tetracycline analogues (doxycycline and COL-3) induce caspase-dependent and -independent apoptosis in human colon cancer cells.

Toshinao Onoda1, Takashi Ono, Dipok Kumar Dhar, Akira Yamanoi, Naofumi Nagasue.   

Abstract

Tetracycline analogues (TCNAs) possess cytotoxic activities as well as matrix metalloproteinase (MMP) inhibitory properties. Previously, we demonstrated that doxycycline (DOXY) could induce apoptosis in human HT29 colon cancer cells. In present study, the molecular apoptotic mechanisms induced by two kinds of TCNAs, designated as DOXY and COL-3 (chemically modified tetracycline-3; 6-demethyl, 6-deoxy, 4-dedimethylamino tetracycline), were evaluated in cultured HT29 cells. Both TCNAs inhibited the proliferation of 6 different colorectal cancer cell lines in a dose-dependent manner. Especially, COL-3 had a stronger effect on cancer cells than DOXY. Apoptotic changes were actually observed by 10 mug/ml COL-3 and 20 mug/ml DOXY in a time-dependent manner. COL-3 produced the increase in cytosolic cytochrome c and the loss of mitochondrial membrane potential after 3 hr treatment, and thereafter activated caspases. In case of DOXY, these changes were observed after 24 hr. Bax translocation was not a prerequisite for cytochrome c releasing in COL-3 treatment. Pretreated pancaspase inhibitor (Z-VAD-FMK) reduced COL-3 and DOXY mediated apoptosis up to 81.3 and 35.3%, as compared with nontreated cells, respectively. These data indicated that TCNAs could induce mitochondria-mediated apoptosis through both caspase-dependent and -independent pathway. In fact, endonuclease G and apoptosis-inducing factor were released into cytosol after the treatment of TCNAs, which indicated that caspase-independent apoptotic pathway is also one of the key mechanisms for the treatment of TCNAs. Taken together, we believe that TCNAs could have strong potentials for clinical application in treating colorectal cancers and improve cancer chemotherapy. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16152604     DOI: 10.1002/ijc.21447

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

Review 1.  Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management.

Authors:  Viswanath Reddy Belum; Andrea Cercek; Virginia Sanz-Motilva; Mario E Lacouture
Journal:  Curr Treat Options Oncol       Date:  2013-09

Review 2.  Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers.

Authors:  Bal L Lokeshwar
Journal:  Pharmacol Res       Date:  2010-11-18       Impact factor: 7.658

3.  Roles of matrix metalloproteinases in the etiology of inguinal hernia.

Authors:  A Aren; A H Gökçe; F S Gökçe; N Dursun
Journal:  Hernia       Date:  2011-07-08       Impact factor: 4.739

4.  Activation of c-Jun N-terminal kinase is essential for mitochondrial membrane potential change and apoptosis induced by doxycycline in melanoma cells.

Authors:  Jiunn-Min Shieh; Tur-Fu Huang; Chi-Feng Hung; Kuan-Hsien Chou; Yih-Jeng Tsai; Wen-Bin Wu
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

5.  The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis.

Authors:  Angelo M Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Joel Moss
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

6.  Preclinical trial on the use of doxycycline for the treatment of adenocarcinoma of the duodenum.

Authors:  Hector R Galván-Salazar; Alejandro D Soriano-Hernández; Daniel A Montes-Galindo; Gabriel Ceja Espíritu; José Guzman-Esquivel; Iram P Rodríguez-Sánchez; Oscar A Newton-Sánchez; Margarita L Martinez-Fierro; Xóchitl G Briseño Gómez; Augusto Rojas-Martínez; Iván Delgado-Enciso
Journal:  Mol Clin Oncol       Date:  2016-09-08

7.  Lowering the apoptotic threshold in colorectal cancer cells by targeting mitochondria.

Authors:  Kevin Sales; Jan-Willem Taanman; Sas Dijk; Marc Winslet; Jayesh Sagar
Journal:  Cancer Cell Int       Date:  2010-09-06       Impact factor: 5.722

8.  OTX2 represses myogenic and neuronal differentiation in medulloblastoma cells.

Authors:  Ren-Yuan Bai; Verena Staedtke; Hart G Lidov; Charles G Eberhart; Gregory J Riggins
Journal:  Cancer Res       Date:  2012-09-17       Impact factor: 12.701

9.  Tetracyclines increase lipid phosphate phosphatase expression on plasma membranes and turnover of plasma lysophosphatidate.

Authors:  Xiaoyun Tang; Yuan Y Zhao; Jay Dewald; Jonathan M Curtis; David N Brindley
Journal:  J Lipid Res       Date:  2016-02-16       Impact factor: 5.922

10.  Does doxycycline work in synergy with cisplatin and oxaliplatin in colorectal cancer?

Authors:  Jayesh Sagar; Kevin Sales; Sas Dijk; JanWillem Taanman; Alexander Seifalian; Mark Winslet
Journal:  World J Surg Oncol       Date:  2009-01-06       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.